At Xalud Therapeutics, we aspire to transform the way chronic inflammatory disease is treated. Patients have waited far too long for a treatment option that addresses the underlying cause of their disease. To meet this need, we are clinically investigating our non-viral pDNA platform in a number of conditions characterized by chronic inflammation.
For more information on the below studies, please visit ClinicalTrials.gov.
Osteoarthritis of the Knee
Title: Efficacy and Safety of XT-150 in Osteoarthritis of the Knee (NCT04124042)
Facet Joint Osteoarthritis
Title: Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis Pain (NCT05196919)
Title: Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain (NCT04466410)
EXPANDED ACCESS POLICY
Xalud is committed to developing promising new therapies to address the unmet medical needs of patients suffering from serious diseases and conditions. Our goal is to provide access to our medicines at the appropriate time and in a manner that is most beneficial to the relevant patient population. We believe focusing on enrollment in our ongoing clinical trials is the safest and most effective way of achieving this goal.
We do recognize that some patients will not be eligible for our clinical trials and may wish to access our investigational products through expanded access. At present, Xalud is evaluating the benefit/risk profile of our investigational therapies and is dedicating all resources available toward developing these therapies to support regulatory approvals. As such, Xalud is currently unable to offer expanded access use of our investigational medicines.
We encourage all patients and physicians who are interested in accessing our investigational medicines to review the information on this page about our clinical trials in progress.
If you have any questions, please reach out to us at email@example.com.
Xalud may revise this expanded access policy at any time.